目次
Table of Content
1. Introduction To Breast Cancer Antibody Drug Conjugates
2. Antibody Drug Conjugates As Breast Cancer Targeted Therapy
2.1 Mechanism Of Antibody Drug Conjugates
2.2 Applications and Advantages In Breast Cancer
2.3 Comparison With Traditional Therapies
2.4 Breast Cancer Antibody Drug Conjugates Combination Therapies
3. Generations Of Breast Cancer Antibody Drug Conjugates
3.1 Antibody Drug Conjugates - Evolution
3.2 Next Generation Antibody Drug Conjugates Prospects
4. Commercially Approved Breast Cancer Antibody Drug Conjugates By Brand Name, Company and Indication
5. Global Breast Cancer Antibody Drug Conjugates Market Outlook
5.1 Current Market Scenario
5.2 Global Breast Cancer Antibody Drug Conjugates Market Trends and Development
5.3 Future Growth Avenues
6. Global Cancer Antibody Drug Conjugates Research and Market Trends By Region
6.1 US
6.2 China
6.3 Europe
6.4 South Korea
6.5 Australia
6.6 Canada
6.7 Japan
6.8 UK
6.9 India
6.10 Latin America
7. Approved Breast Cancer Antibody Drug Conjugates - Patent, Dosage and Price Analysis
This Chapter Gives Insight On 7 Approved Breast Cancer Antibody Drug Conjugates 7.1 Kadcyla
7.1.1 Overview, Availability and Patent Insight
7.1.2 P ricing and Dosage Insight
.
.
.
.
7.7 Aidixi
7.7.1 Overview and Availability Insight
8. Approved Breast Cancer Antibody Drug Conjugates Sales Insights
8.1 Kadcyla
8.2 Enhertu
8.3 Trodelvy
8.4 Datroway
9. Global Cancer Antibody Drug Conjugates Clinical Trials Overview
9.1 By Phase
9.2 By Indication
9.3 By Company
9.4 By Country
10. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Phase II
10.6 Phase I/III
10.7 Phase III
10.8 Preregistration
10.9 Registered
11. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
12. Cancer Antibody Drug Conjugates Development Platforms By Company
13. Global Cancer Antibody Drug Conjugates Market Overview
13.1 Key Market Growth Drivers
13.2 Challenges For Market Growth
14. Competitive Landscape
14.1 ADC Therapeutics
14.2 AstraZeneca
14.3 Biocytogen
14.4 Biokin
14.5 Bristol Myers Squibb
14.6 Daiichi Sankyo
14.7 Duality Biologics
14.8 Eli Lilly
14.9 Gilead
14.10 Immunogen
14.11 Innovent Biologics
14.12 LigaChem Biosciences
14.13 Merck
14.14 Pfizer
14.15 Roche
List of Figures & Tables
Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
Figure 2-2: Advantages Of Antibody Drug Conjugates
Figure 2-3: Antibody Drug Conjugate Combinations In Studies
Figure 3-1: Cancer Antibody Drug Conjugates - Opportunities For Next Generation Development
Figure 5-1: Global - Breast Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 5-2: Global - Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), H1’2025
Figure 5-3: Global - Cancer Antibody Drug Conjugate Market Share By Drugs (%), H1’2025
Figure 5-4: Global - Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 and Q2’2025
Figure 5-5: Global - Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), 2024
Figure 5-6: Global - Breast Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2024
Figure 5-7: Global - Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 -Q4’2024
Figure 5-8: Global - Breast Cancer Antibody Drug Conjugate Market By Drugs (US$ Million), 2023
Figure 5-9: Global - Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2023
Figure 5-10: D926QC00001 Phase 3 (NCT06112379) Study - Initiation and Completion Year
Figure 5-11: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation and Completion Year
Figure 5-12: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation and Completion Year
Figure 5-13: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation and Completion Year
Figure 5-14: Global - Breast Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2026 - 2030
Figure 6-1: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), September’2025
Figure 7-1: US - Kadcyla FDA Approval Year By Indication
Figure 7-2: Kadcyla - Approval Year By Region
Figure 7-3: US - Kadcyla FDA Approval and Patent Expiration Year
Figure 7-4: Kadcyla - Cost of Supply In US and Europe (US$), September’2025
Figure 7-5: Kadcyla - Recommended Dose after 1st and 2nd Dose Reduction (mg/kg)
Figure 7-6: Enhertu - Approval Year By Region
Figure 7-7: US - Polivy FDA Approval Year by Indication
Figure 7-8: Enhertu - FDA Orphan Drug Designation and Exclusivity Expiration Year
Figure 7-9: Enhertu - Cost of 100 mg Supply In US and Europe (US$), September’2025
Figure 7-10: US - Trodelvy FDA Approval by Indication
Figure 7-11: Trodelvy - Approval Year By Region
Figure 7-12: Trodelvy - Patent Expiration By Region
Figure 7-13: Trodelvy - Cost of Supply In US and Europe (US$), September’2025
Figure 7-14: Ujvira - Cost of 100 mg and 160 mg Supply in India (US$), September’2025
Figure 7-15: Datroway - Cost of 100 mg Supply In US and Europe (US$), September’2025
Figure 8-1: Kadcyla - Global Sales (US$ Million), 2020-2025
Figure 8-2: Kadcyla - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-3: Kadcyla - Global Sales By Region (%), H1’2025
Figure 8-4: Kadcyla - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-5: Kadcyla - Global Sales By Region (US$ Million), 2024
Figure 8-6: Kadcyla - Global Sales By Region (%), 2024
Figure 8-7: Kadcyla - US Annual Sales (US$ Million), 2020-2025
Figure 8-8: Kadcyla - US Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-9: Kadcyla - US Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-10: Kadcyla - Europe Annual Sales (US$ Million), 2020-2025
Figure 8-11: Kadcyla - Europe Quarterly Sales (US$ Million), Q1’2025
Figure 8-12: Kadcyla - Europe Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-13: Kadcyla - Japan Annual Sales (US$ Million), 2020-2025
Figure 8-14: Kadcyla - Japan Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-15: Kadcyla - Japan Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-16: Kadcyla - ROW Annual Sales (US$ Million), 2020-2025
Figure 8-17: Kadcyla - ROW Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-18: Kadcyla - ROW Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-19: Enhertu - Global Annual Sales (US$ Million), 2020-2025
Figure 8-20: Enhertu - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-21: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-22: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
Figure 8-23: Trodelvy - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-24: Trodelvy - Annual Sales By Region (US$ Million), 2025
Figure 8-25: Trodelvy - Annual Sales By Region (%), 2025
Figure 8-26: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-27: Trodelvy - Annual Sales By Region (US$ Million), 2024
Figure 8-28: Trodelvy - Annual Sales By Region (%), 2024
Figure 8-29: Trodelvy - US Annual Sales (US$ Million), 2020-2025
Figure 8-30: Trodelvy - US Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-31: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-32: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
Figure 8-33: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-34: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-35: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
Figure 8-36: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 8-37: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 8-38: Datroway - Global Annual Sales (US$ Million), 2025
Figure 8-39: Datroway - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 9-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
Figure 9-2: Global- Cancer Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
Figure 9-3: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
Figure 9-4: Global - Cancer Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030
Figure 12-1: Proprietary ADC Technology - Seagen
Figure 12-2: ALE.P02 and ALE.P03 - Alentis Therapeutics
Figure 12-3: TRAAC - Tallac Therapeutics
Figure 12-4: ATAC - Heidelberg Pharma
Figure 12-5: Tub-tagandreg; and P5 - Tubulis
Table 2-1: Comparison Between Antibody Drug Conjugates and Traditional Cancer Therapies
Table 2-2: Breast Cancer - Ongoing Antibody Drug Conjugate Combination Clinical Trials
Table 3-1: Breast Cancer - Approved Second Generation Antibody Drug Conjugates
Table 3-2: Breast Cancer - Approved Third Generation Antibody Drug Conjugates
Table 3-3: Fourth Generation Antibody Drug Conjugates - Examples
Table 4-1: Breast Cancer - Approved Antibody Drug Conjugates, September’2025
Table 5-1: Breast Cancer - Approved Antibody Drug Conjugates
Table 6-1: US - Approved Breast Cancer Antibody Drug Conjugates, September’2025
Table 6-2: China - Approved Antibody Drug Conjugates, September’2025
Table 6-3: EU - Approved Cancer Antibody Drug Conjugates, September’2025
Table 6-4: Australia - Approved Cancer Antibody Drug Conjugates, September’2025
Table 6-5: Canada - Approved Cancer Antibody Drug Conjugates, September’2025
Table 6-6: Japan - Approved Cancer Antibody Drug Conjugates, September’2025
Table 6-7: UK - Approved Antibody Drug Conjugates, September’2025
Table 7-1: Datroway - Premedication and Concomitant Medications
Table 7-2: Datroway - Recommended Dosage Reductions for Adverse Reactions
